CSS
ACHL

Cubist Systematic Strategies’s Achilles Therapeutics ACHL Stock Holding History

Cubist Systematic Strategies’s Portfolio ACHL Stock Details ACHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,085
Closed -$2K – 4671
2022
Q3 		$2K Buy
1,085
+400
+58% +$1.13K ﹤0.01% 4355
2022
Q2 		$2K Buy
685
+100
+17% +$247 ﹤0.01% 4321
2022
Q1 		$2K Sell
585
-425
-42% -$1.51K ﹤0.01% 3518
2021
Q4 		$5K Sell
1,010
-875
-46% -$5.3K ﹤0.01% 3410
2021
Q3 		$15K Buy
+1,885
New +$12.4K ﹤0.01% 2898

Other funds holding ACHL

SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Cubist Systematic Strategies's ACHL Position: Q4 2022 in Review

Cubist Systematic Strategies sold out of Achilles Therapeutics (ACHL) in Q4 2022, closing a stake of 1,085 shares — an estimated $2K sold.

Cubist Systematic Strategies first reported a position in ACHL in Q3 2021 and held it in 5 quarters. The position peaked at $15K in Q3 2021. 23 funds tracked by Wall St. Rank hold ACHL as of Q4 2022.

  • Cubist Systematic Strategies reported no remaining Achilles Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Cubist Systematic Strategies sold 1,085 Achilles Therapeutics shares in Q4 2022, an estimated $2K.
  • Cubist Systematic Strategies first reported a position in Achilles Therapeutics in Q3 2021 and held it in 5 quarters.
  • Cubist Systematic Strategies's Achilles Therapeutics position peaked at $15K in Q3 2021.
  • 23 funds tracked by Wall St. Rank held Achilles Therapeutics as of Q4 2022.

Based on Cubist Systematic Strategies's 13F filing for Q4 2022, filed 14 Feb 2023.